Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
Watch for follow-on moves from competitors and reactions from key channel partners in the coming quarters.
À l’occasion du congrès HLTH Europe 2026, le King Faisal Specialist Hospital présente son écosystème d’IA appliquée en …
Ahmad AbuSalah, Direktor des Digital Innovation Hub am King Faisal Specialist Hospital & Research Centre (KFSH), stellt…
Professor Ahmad AbuSalah, PhD, Director of the Digital Innovation Hub at King Faisal Specialist Hospital & Research Cen…
Aplagon Announces EUR 5 Million Financing to Broaden Phase 2 Trials of its APAC Therapy in Thrombo-Inflammatory Diseases
REYKJAVIK, ICELAND (June 16, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechn…
júní 2026) - Alvotech (NASDAQ: ALVO, ALVO SDB) kynnti í dag ákvörðun um verð og úthlutun í áður boðuðu sölutryggðu hlut…
The Nasdaq-listed kefir pioneer uses experiential retail to drive category awareness as fermented dairy's probiotic cre…
How Dignitas Pokémon UNITE utilized advanced cognitive support to dominate the NAIC and redefine wellness in esports.
MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine has built a differen…
-- Setmelanotide therapy achieved robust, sustained and clinically significant weight loss in patients with acquired HO…